Eyup Çağatay ZENGİN, Ali ÇETİN, Zübeyde AKIN POLAT

Effects of pentoxifylline on proliferation of human umbilical vein endothelial cells (HUVEC)

Bu çalışmanın amacı farmokolojik doz aralığında uygulanan pentoksifilinin insan umblikal ven endotel hücrelerinin (HUVEC) proliferasyonu üzerine etkisini araştırmaktır. Yöntem: Hücreler içerisine %20 fetal bovine serum, penisilin ve streptomisin eklenen M199 besiyeri içinde, %5 CO2 içeren 37 C 'lik inkübatörde kültüre edildi. Deneyler hücreler gelişim fazında iken gerçekleştirildi. Hücrelerin canlılığı kültür ortamına tetrazolium tuzları eklenerek değerlendirildi. Pentoksifilinin 10-4M, 10-5M, 10-6M and 10-7M konsantrasyonları, 24, 48 ve 72. saatlerde değerlendirildi. Deneyler altı tekrarlı yapıldı. Bulgular: Pentoksifilinin sadece 10-4 M dozu 72. saatte HUVEC proliferasyonunu düşürdü (p0.05). Sonuç: Genel olarak, pentoksifilinin farmakolojik dozlar aralığında HUVEC hücreleri üzerine sitotoksik etkisi bulunmamaktadır. Bu sonuç, pentoksifilinin normal ve iskemik dokulardaki pozitif etkilerini gösteren çeşitli deneysel ve klinik araştırmaların sonuçları ile uyumlu bulunmaktadır

Pentoksifilinin insan göbek bağı veni endotel hücrelerinin (HUVEC) proliferasyonu üzerine etkisi

The aim of this study was to investigate the effect of pentoxifylline (PNX) with a pharmacological dose range on proliferation of human umblical venous endothelial cells (HUVEC). Method: The cells were maintained in M199 supplemented with 20% fetal bovine serum, penicillin, and streptomycin. The cultures were cultivated in an incubator at 37°C and with 5% CO2, until cell monolayers attained confluence which occurred after 7 days. The assays were performed in the exponential growth phase of the cells. The cell viability was assessed using the cleavage of tetrazolium salts added to the culture medium. Pentoxifylline with concentrations of 10-4M, 10-5M, 10-6M and 10-7M were used for the proliferation assay in which cells were incubated for 24, 48, and 72-hours with these drugs. The experiments were conducted in six replicates. Results: Only the 10-4M dose of PNX at 72 h significantly reduced the viability of HUVEC (p0.05). Conclusions: Overall, PTX with a pharmacological dose range has no cytotoxic effect on HUVEC. We think that this is also in accordance with the findings of several studies performed in animal models and clinical settings, indicating positive effects of PTX on tissues in normal and ischemic conditions

PDF

___

Nasiri-Toosi Z, Dashti-Khavidaki S, Khalili H, Lessan-Pezeshki M. A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity. Eur J Clin Pharmacol 2013; 69: 1057-73. 2. Samlaska Pentoxifylline.
Dermatol 1994; 30: 603-21.
Kreth S, Ledderose C, Luchting B, Weis
Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent
Shock 2010; 34: 10-6.
Savic V, Vlahovic P, Djordjevic V, Mitic-Zlatkovic M, Avramovic V, Stefanovic V. Nephroprotective effects
experimental myoglobinuric acute renal failure. Pathol Biol (Paris) 2002; 50: 599-607.
Coe DA, Freischlag JA, Johnson D, Mudaliar JH, Kosciesza SA, Traul DK, Chiang PC, Cambria RA, Seabrook
Pentoxifylline prevents endothelial damage due to ischemia and reperfusion injury. J Surg Res 1997; 67: 21-5.
Normandin L, Hervé P, Brink C, Chapelier AR, Dartevelle PG, Mazmanian GM. L-arginine and pentoxifylline attenuate endothelial dysfunction after lung reperfusion injury in the rabbit. The Paris-Sud University Lung Transplant Group. Ann Thorac Surg 1995; 60: 646-50. 7.
Dauber IM, Lesnefsky EJ, Ashmore RC, Martel DM, Sheridan FM, Weil JV, Horwitz LD. Coronary vascular injury due to ischemia-reperfusion is reduced by pentoxifylline. J Pharmacol Exp Ther 1992; 260: 1250-6. 8.
Teruya R, Fagundes DJ, Oshima CT, Brasileiro JL, Marks G, Ynouye CM, Simões MJ. The effects of pentoxifylline into the kidneys of rats in a model of unilateral hindlimb
injury. Acta Cir Bras 2008; 23: 29- 35.
Genovés P, García D, Cejalvo D, Martin A, Zaragoza C, Toledo AH, Toledo-Pereyra LH, Lloris-Carsi JM. Pentoxifylline in liver ischemia and reperfusion. J Invest Surg. 2014; 27: 114-24.
Hoie EB, McGuire TR, Leuschen PM,
inhibits tumor necrosis factor-alpha induced synthesis of complement component C3 in human endothelial cells. Biol Pharm Bull 2004; 27: 1670-3.
Franzini E, Sellak H, Babin- Chevaye C, Hakim J, Pasquier C. Effects of pentoxifylline on the adherence of polymorphonuclear neutrophils to oxidant-stimulated human
involvement of cyclic AMP. J Cardiovasc Pharmacol 1995; 25: 92-5.
cells: 12. Lloris Carsi JM, Cejalvo Lapeña D, Toledo AH, Zaragoza Fernandez C, Toledo Pereyra LH. Pentoxifylline protects the small intestine after severe ischemia and reperfusion. Exp Clin Transplant 2013; 11: 250- 8.
Taha H, Grochot-Przeczek A, Was H, Kotlinowski J, Kozakowska M, Marek A, Skrzypek K, Lackowska B, Balcerczyk A, Mustafa S, Dulak J, Jozkowicz A. Modulation of inflammatory
pentoxifylline is independent of heme oxygenase-1 pathway. J Physiol Pharmacol 2009; 60: 3-12. 14. Gude RP, Binda MM, Boquete AL, Bonfil RD. Inhibition of endothelial cell proliferation and tumor-induced angiogenesis by pentoxifylline. J Cancer Res Clin Oncol 2001; 127: 625-30.